文献速递胸部肿瘤

ALK酪氨酸激酶抑制剂治疗后非小细胞肺癌新型耐药机制:L1196Q、P1094H及R1248_D1249插入

Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor Treatment.
PubMed 文献 · J Thorac Oncol · 2020-11-06

该研究对21例ALK阳性NSCLC患者在ALK TKI治疗失败后重新活检,进行ALK FISH和RT-PCR分析,发现9例无已知ALK耐药机制,4例ALK扩增,各1例检出L1196M、I1171N、G1269A,各1例小细胞癌和肉瘤样转化,二代ALK TKI后检出L1196Q、P1094H和外显子24的76碱基对插入。结论认为基因分析联合计算模拟模型或可预测耐药机制。

要点

  • 21例ALK阳性NSCLC再活检中9例无已知ALK耐药机制,4例ALK扩增。
  • 已知耐药突变L1196M、I1171N、G1269A各检出1例。
  • 二代ALK TKI后检出L1196Q、P1094H和外显子24的76碱基对插入。

核心结论

  • 基因分析与计算模拟模型联合可能预测ALK TKI耐药机制,有助于克服耐药。
  • 构建基因组与模拟融合数据库对个性化医疗重要。

研究设计与样本

  • 纳入21例ALK阳性NSCLC患者,均在ALK TKI失败后接受再活检。
  • 对配对初诊和再活检肿瘤标本进行ALK FISH和RT-PCR。

主要发现

  • 9例患者无已知ALK耐药机制。
  • 4例检出ALK扩增。
  • L1196M、I1171N、G1269A各检出1例。
  • 小细胞癌转化和肉瘤样转化各1例。
  • 二代ALK TKI后检出L1196Q、P1094H和外显子24的76碱基对插入。

临床怎么用

  • ALK TKI失败后应考虑再活检行ALK FISH和RT-PCR以明确耐药机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purposes of this study are to clarify the details of the ALK tyrosine kinase inhibitor (TKI) resistance mechanism in rebiopsy cases and to predict novel resistance gene alterations using molecular dynamics simulation. METHODS: A total of 21 patients with ALK-positive NSCLC who underwent a rebiopsy after ALK TKI failure were included in this analysis. ALK fluorescence in situ hybridization and reverse transcription polymerase chain reaction were performed with paired initial and rebiopsy tumor specimens. RESULTS: Nine patients had no known ALK resistance mechanisms. Four had ALK amplification. L1196M, I1171N, and G1269A, mutations that are known to indicate resistance to ALK TKIs, were detected in one patient each. Small cell carcinoma and sarcomatoid transition were found in one case each. L1196Q, P1094H, and exon 24 76-base pair insertion were detected after the second-generation ALK TKIs. CONCLUSIONS: The combination of a genetic analysis and a computational simulation model may make a prediction of resistance mechanisms for overcoming ALK TKI resistance, and the construction of a genomic and simulation fused database is important for the development of personalized medicine in this field.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Furuta H, Araki M, Masago K, et al. Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor Treatment. J Thorac Oncol. 2020. PMID: 33166721. doi:10.1016/j.jtho.2020.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。